Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 12/20 | 0.43 |
| ▸ | THRA | P10827 | 10/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | CETP | P11597 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7114452 | 0.87 | THRB (0.50) | THRBTHRACA2GAAPOLB | |
| SCHEMBL6864460 | 0.86 | THRB (0.48) | THRBTHRACA2GAAPOLB | |
| SCHEMBL282445 | 0.86 | THRB (0.49) | THRBTHRACA2RORCCETP | |
| SCHEMBL10105507 | 0.83 | THRB (0.47) | THRBTHRA | |
| SCHEMBL667473 | 0.80 | THRB (0.45) | THRBTHRARORCOPRK1ALDH1A1 | |
| SCHEMBL667776 | 0.79 | THRB (0.39) | THRBTHRACA2GAAPOLB | |
| SCHEMBL7590192 | 0.79 | ALDH1A1 (0.43) | THRBTHRAGAAALDH1A1ALOX12 | |
| SCHEMBL6864242 | 0.79 | THRB (0.49) | THRBTHRARORCOPRK1 | |
| SCHEMBL7599524 | 0.77 | THRB (0.47) | THRBTHRAOPRK1 | |
| SCHEMBL26661435 | 0.77 | CNR2 (0.45) | THRBCA2GAAPOLBGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046364-A1 | Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use | METABASIS THERAPEUTICS, INC. (US) | 2012-02-23 | — | — | US | disclosed |
| US-20120046364-A1 | Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use | METABASIS THERAPEUTICS, INC. (US) | 2012-02-23 | — | — | US | disclosed |
| WO-2010093601-A1 | NOVEL SULFONIC ACID-CONTAINING THYROMIMETICS, AND METHODS FOR THEIR USE | METABASIS THERAPEUTICS, INC. (US) | 2010-08-19 | — | — | WO | disclosed |
| WO-2010093601-A1 | NOVEL SULFONIC ACID-CONTAINING THYROMIMETICS, AND METHODS FOR THEIR USE | METABASIS THERAPEUTICS, INC. (US) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046364-A1 | Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use | THRB, TSHR, THRA | THRB 1/4885THRA 3/4885CA2 2873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.